tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Immix Biopharma receives strategic investment from Goose Capital
PremiumThe FlyImmix Biopharma receives strategic investment from Goose Capital
2M ago
Immix Biopharma announces ‘class-leading’ safety profile for NXC-201
Premium
The Fly
Immix Biopharma announces ‘class-leading’ safety profile for NXC-201
4M ago
Immix Biopharma’s Strategic Expansion and Promising Trial Results Reinforce Buy Rating
Premium
Ratings
Immix Biopharma’s Strategic Expansion and Promising Trial Results Reinforce Buy Rating
4M ago
Immix Biopharma Enters At The Market Offering Agreement
PremiumCompany AnnouncementsImmix Biopharma Enters At The Market Offering Agreement
5M ago
Immix Biopharma announces NXC-201 trial met primary endpoint
Premium
The Fly
Immix Biopharma announces NXC-201 trial met primary endpoint
5M ago
Immix Biopharma expands U.S. clinical sites for NEXICART-2 trial
Premium
The Fly
Immix Biopharma expands U.S. clinical sites for NEXICART-2 trial
5M ago
Immix Biopharma announces publication of NXC-201 clinical results
PremiumThe FlyImmix Biopharma announces publication of NXC-201 clinical results
11M ago
Immix Biopharma reports 75% CRR for NXC-201 in r/r AL amyloidosis patients
Premium
The Fly
Immix Biopharma reports 75% CRR for NXC-201 in r/r AL amyloidosis patients
11M ago
Immix Biopharma: Ex-US study of NXC-201 produced 92% ORR in r/r AL Amyloidosis
Premium
The Fly
Immix Biopharma: Ex-US study of NXC-201 produced 92% ORR in r/r AL Amyloidosis
1y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100